Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial

Published:2022-09 Issue: Volume:51 Page:101569
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Song Joon Young^ORCID,Choi Won Suk,Heo Jung Yeon,Lee Jin Soo,Jung Dong Sik,Kim Shin-Woo,Park Kyung-Hwa,Eom Joong Sik,Jeong Su Jin,Lee Jacob,Kwon Ki Tae,Choi Hee Jung,Sohn Jang Wook,Kim Young Keun^ORCID,Noh Ji Yun,Kim Woo Joo,Roman François,Ceregido Maria Angeles,Solmi Francesca,Philippot Agathe,Walls Alexandra C.,Carter Lauren,Veesler David^ORCID,King Neil P.,Kim Hun,Ryu Ji Hwa,Lee Su Jeen^ORCID,Park Yong Wook,Park Ho Keun,Cheong Hee Jin

Publisher

Elsevier BV

Subject

General Medicine

Reference24 articles.

1. World Health Organization. Coronavirus disease 2019 (COVID-19): situation report. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed 31 January 2022.

2. Scientific rationale for developing potent RBD-based vaccines targeting COVID-19;Kleanthous;NPJ Vaccines,2021

3. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2;Walls;Cell,2020

4. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology;Piccoli;Cell,2020

5. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein;Walls;Cell,2020

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functionally Designed Nanovaccines against SARS-CoV-2 and Its Variants;Vaccines;2024-07-12

2. A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines;Nature Communications;2024-06-28

3. Advances in virus-like particle-based SARS-CoV-2 vaccines;Frontiers in Cellular and Infection Microbiology;2024-06-26

4. Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac®) as a Booster Dose against COVID-19 in Indonesian Adults;Vaccines;2024-05-14

5. Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study;Expert Review of Vaccines;2024-05-02